# DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct06382168/  
OnCo record `nct06382168` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by Delta-Fly Pharma, Inc., now recruiting.

## Summary

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06382168 by Delta-Fly Pharma, Inc., with 39 participants planned, started 2024-06-12 and due to reach its primary completion in 2026-03-31. Interventions recorded: DFP-10917 and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06382168
- Phase: 1/2
- Setting: Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- Sponsor: Delta-Fly Pharma, Inc.
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06382168: https://clinicaltrials.gov/study/NCT06382168

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06382168.json